MAP2K5 and neoplasm: Western blot analyses, performed on tumours removed from mice on the last day of the experiment, indicated that trametinib abolished the phosphorylation of ERK1/2 in both scrambled cells and clones lacking MEK5 (Figures 5I and 5J left and Figure S3I).